Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway

Beat Bornhäuser(University Children's Hospital Zurich), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Gunnar Cario, Felix Niggli(University of Zurich), Beat W. Schäfer(University Children's Hospital Zurich), Dan Lindholm(Linköping University), Laura Bonapace(University Children's Hospital Zurich), Martin Schrappe(University Hospital Schleswig-Holstein)

Blood

May 30, 2007

10.1182/blood-2006-12-060970

Cited by 62

Related Papers

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

|Journal of Clinical Oncology|2015|1k

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

|The Lancet|1998|964

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

|Blood|2008|607

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

|The Lancet|2002|401

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

|Blood|2009|347